Ascendis Pharma Reports Strong Q1 2026 on YORVIPATH Growth and YUVIWEL Launch

Event summary

  • Q1 2026 revenue of €247 million, up from €101 million in Q1 2025, driven by YORVIPATH sales.
  • YORVIPATH enrolled over 1,000 new patients in the U.S. in Q1 2026.
  • YUVIWEL received FDA accelerated approval in February 2026, with over 60 patient enrollments by May 1, 2026.
  • Company sold Rare Pediatric Disease Priority Review Voucher for $187.5 million.

The big picture

Ascendis Pharma's Q1 2026 results highlight its transition from a development-stage biotech to a commercial-stage player, with YORVIPATH as its growth engine. The FDA approval of YUVIWEL and its early adoption signal potential in the rare disease space, while the PRV sale underscores the company's ability to monetize regulatory assets. The biopharma sector is increasingly valuing commercial execution and pipeline diversification, and Ascendis is positioning itself as a key player in both.

What we're watching

Commercial Momentum
Whether Ascendis can sustain YORVIPATH's rapid patient uptake and expand YUVIWEL's market reach.
Regulatory Milestones
The pace at which YUVIWEL gains approval in Europe and advances through label expansion trials.
Financial Strategy
How Ascendis allocates proceeds from the $187.5 million PRV sale to fuel further growth.